Forward P/S Multiple: RXi Pharmaceuticals (PHIO)
Phio Pharmaceuticals (PHIO) maintains its pioneer status in developing INTASYL self-delivering RNA therapies for tumor combat. Current portfolio diversification through gene silencing in skin and organ tissues complements this foundation. Stable laboratory operations ensure research continuity. The company's expected P/S ratio demonstrates a balance between these factors, while the metric reflects the current dynamics of alignment between market valuation and margin forecasts.
Metric breakdowns and analytics for phiopharma.com (PHIO)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Phio Pharmaceuticals|PHIO - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Phio Pharmaceuticals Corp.|PHIO - Company Cumulative Indebtedness|Debts to Book Capitalization PHIO|PHIO - Long-Term Debt Volume|Company Short-Term Debts Phio Pharmaceuticals|Quick Ratio phiopharma.com
- financial results and valuation multiples details:
PHIO - Net Profit|Expected Profit Phio Pharmaceuticals|PHIO - Price to Earnings Ratio|Future Price to Earnings Phio Pharmaceuticals Corp.|PHIO - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PHIO|PHIO - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Phio Pharmaceuticals|PHIO - Earnings per share for the trailing year|Quarterly EPS earnings growth phiopharma.com|PHIO - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Phio Pharmaceuticals
- sales and revenue data:
General company analysis:RXi Pharmaceuticals PHIO
Analyzing the current forward P/S ratio allows for an assessment of the market value of Phio Pharmaceuticals (PHIO) relative to expected revenues from the implementation of RNA technologies in immuno-oncology. This metric compares market capitalization with projected revenue, making it possible to determine the justification for the control premium over assets and evaluate the company's investment attractiveness in the context of seeking strategic partners to develop cancer treatment programs.
Analysis of competing companies
Price-to-Projected Revenue Ratio Tempus AI, Inc. TEM|QGEN - Forward Price-to-Revenue Multiple|Ionis Pharma - Forward P/S Multiple|RGEN - Forward P/S Multiple|RNA: Forward P/S Multiple|Forward Price-to-Revenue Multiple crisprtx.com|WGS (GeneDx) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Ultragenyx Pharmaceutical Inc. RARE|Forward Price-to-Revenue Multiple BEAM (Beam Therapeutics Corp)|Forward P/S Multiple Sarepta Corp (SRPT)|Twist Bioscience - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio TXG (10xgenomics.com)|Intellia Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Stoke Therapeutics Inc STOK|BLFS: Forward P/S Multiple|Forward Price-to-Revenue Multiple Wave Pharma|MAZE (Maze Therapeutics Inc) - Forward P/S Multiple|Forward P/S Multiple sionnatx.com|Price-to-Projected Revenue Ratio Prime Medicine (PRME)|Price-to-Projected Revenue Ratio TSHA (Taysha Gene Therapies Inc)|Price-to-Projected Revenue Ratio uniQure Corp QURE|Market Cap to Expected Sales Ratio MeiraGTx Corp (MGTX)|RGNX - Price-to-Projected Revenue Ratio|Future Price to Revenue SLDB|OCGN: Forward P/S Multiple|Pacific Biosciences of California, Inc. - Forward Price to Sales|BNTC (Benitec) - Forward P/S Multiple|Design Corp (DSGN) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Rocket Pharmaceuticals (RCKT)|FDMT - Market Cap to Future Revenue Ratio|Forward P/S Multiple LXEO (Lexeo Therapeutics, Inc.)|KRRO: Market Cap to Projected Revenue|EDIT - Price-to-Projected Revenue Ratio|SLN (Silence Therapeutics Corp) - Market Cap to Projected Revenue|PRQR: Forward P/S Multiple|Codexis (CDXS) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Sangamo Therapeutics, Inc.|Nautilus Biotechnology Inc - Future Price to Revenue|Forward P/S Multiple MGX|DTIL (Precision BioSciences Inc.) - Forward Price to Sales|Forward P/S Multiple GBIO (Generation Bio)|Market Cap to Expected Sales Ratio boundlessbio.com (BOLD)|XCUR - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Imunon, Inc.|MBIO (mustangbio.com) - Forward Price-to-Revenue Multiple|TransCode Therapeutics, Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Bionano Genomics Inc.|adnas.com - Future Price to Revenue|Forward P/S Multiple BLUE|IPA (immunoprecise.com) - Forward Price to Sales|Forward P/S Multiple OMGA (Omega)|Forward P/S Multiple Singular Genomics Corp OMIC|RGLS - Price-to-Projected Revenue Ratio|Forward Price to Sales SYRS (syros.com)|Telesis Bio (TBIO) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple TRACON Pharmaceuticals Inc.|UBX (Unity Bio) - Forward P/S Multiple
